Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease
| Autor: | Cristina Cudalbu, Paola Mastromarino, Emmanuelle Flatt, Olivier Braissant, Valérie A. McLin, Sharon DeMorrow, Veronika Rackayova, Matthew McMillin, Jocelyn Grosse, Daniela Capobianco |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Blood Glucose Male Cirrhosis Glutamine Proton Magnetic Resonance Spectroscopy gut microbiome Pharmacology Chronic liver disease law.invention Probiotic Lactulose Feces 0302 clinical medicine law Ammonium Compounds Hepatic encephalopathy Multidisciplinary Cholestasis Behavior Animal Brain 3. Good health Experimental models of disease Tolerability randomized controlled-trial Disease Progression Metabolome Medicine 030211 gastroenterology & hepatology medicine.symptom medicine.drug metaanalysis spectroscopy Science Inflammation Article 03 medical and health sciences NMR spectroscopy In vivo medicine Animals bacterial translocation Rats Wistar Ligation Liver diseases minimal hepatic-encephalopathy Hepatology business.industry cirrhosis Probiotics Body Weight Bilirubin medicine.disease Gastrointestinal Microbiome 030104 developmental biology inflammation Preclinical research lactulose Bifidobacterium Bile Ducts business Neurological disorders Inositol |
| Zdroj: | Scientific Reports Scientific reports, vol. 11, no. 1, pp. 2269 Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| ISSN: | 2045-2322 |
| Popis: | Chronic liver disease leads to neuropsychiatric complications called hepatic encephalopathy (HE). Current treatments have some limitations in their efficacy and tolerability, emphasizing the need for alternative therapies. Modulation of gut bacterial flora using probiotics is emerging as a therapeutic alternative. However, knowledge about how probiotics influence brain metabolite changes during HE is missing. In the present study, we combined the advantages of ultra-high field in vivo 1H MRS with behavioural tests to analyse whether a long-term treatment with a multistrain probiotic mixture (VIVOMIXX) in a rat model of type C HE had a positive effect on behaviour and neurometabolic changes. We showed that the prophylactic administration of this probiotic formulation led to an increase in gut Bifidobacteria and attenuated changes in locomotor activity and neurometabolic profile in a rat model of type C HE. Both the performance in behavioural tests and the neurometabolic profile of BDL + probiotic rats were improved compared to the BDL group at week 8 post-BDL. They displayed a significantly lesser increase in brain Gln, a milder decrease in brain mIns and a smaller decrease in neurotransmitter Glu than untreated animals. The clinical implications of these findings are potentially far-reaching given that probiotics are generally safe and well-tolerated by patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|